These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 9217923)
21. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? Schwartz-Albiez R; Laban S; Eichmüller S; Kirschfink M Autoimmun Rev; 2008 Jun; 7(6):491-5. PubMed ID: 18558368 [TBL] [Abstract][Full Text] [Related]
22. The hairy powers of oncogenes: from biological function to cancer therapy. Polyak K Cancer Biol Ther; 2003; 2(5):592-4. PubMed ID: 14614334 [No Abstract] [Full Text] [Related]
23. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer. Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945 [No Abstract] [Full Text] [Related]
24. Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Vitetta ES; Krolick KA; Uhr JW Immunol Rev; 1982; 62():159-83. PubMed ID: 7042537 [No Abstract] [Full Text] [Related]
28. Idiotypic responses induced by tumor: an autocrine network. Köhler H; Raychaudhuri S; Chen JJ; Saeki Y Int Rev Immunol; 1989; 4(4):311-20. PubMed ID: 2535274 [No Abstract] [Full Text] [Related]
29. [Effect of hyperthermia on the immunological system with regard to antineoplastic immunity]. Roszkowski W Postepy Hig Med Dosw; 1981; 35(5):451-70. PubMed ID: 6752919 [No Abstract] [Full Text] [Related]
35. The translational potential for target validation and therapy using intracellular antibodies in oncology. Weidle UH; Maisel D; Brinkmann U; Tiefenthaler G Cancer Genomics Proteomics; 2013; 10(6):239-50. PubMed ID: 24336633 [TBL] [Abstract][Full Text] [Related]
36. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Germain C; Larbouret C; Cesson V; Donda A; Held W; Mach JP; Pèlegrin A; Robert B Clin Cancer Res; 2005 Oct; 11(20):7516-22. PubMed ID: 16243826 [TBL] [Abstract][Full Text] [Related]
37. Immune RNA in the immunotherapy of cancer. Pilch YH; Fritze D; Kern DH Med Clin North Am; 1976 May; 60(3):567-83. PubMed ID: 1271893 [No Abstract] [Full Text] [Related]
38. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target. Al-Rammahy AK; Levy JG Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763 [No Abstract] [Full Text] [Related]
39. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763 [TBL] [Abstract][Full Text] [Related]
40. Bi-specific antibodies in cancer therapy. Wang H; Liu Y; Wei L; Guo Y Adv Exp Med Biol; 2000; 465():369-80. PubMed ID: 10810641 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]